People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Semaglutide (Ozempic, Wegovy) may help reduce the risk of an opioid overdose in certain people, an emulation target trial ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

The companies will deliver products for diabetes and weight control in specific nations across the Middle East.

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...